- Free Express Shipping on Orders $200+
- Get Premium-Grade Peptides and Save When You Buy in Bundles
- Made in the USA
$44.99
Semax from Epic Peptides Lab is a research-use-only compound supplied in a preloaded 3ml Disposable Self-injection Pen at 1mg/ml for laboratory study, offering consistent measured delivery and reliable handling for researchers.
Epic Peptides Lab · Research Use Only
ACTH(4-7)-PGP analog · heptapeptide · 3ml at 1mg/ml
The Semax Disposable Self-injection Pen is a preloaded 3ml research device containing Semax in solution at 1mg/ml, giving 3mg of total peptide. Semax is a seven-residue peptide, CAS 80714-61-0, molecular weight 813.93, comprising the adrenocorticotropic hormone fragment ACTH(4-7) extended by a C-terminal Pro-Gly-Pro tail.
| Property | Value |
|---|---|
| Device format | Preloaded Disposable Self-injection Pen, glass cartridge |
| Fill volume | 3 ml |
| Concentration | 1 mg/ml |
| Total compound in device | 3 mg |
| Molar concentration | Approximately 1.23 mM |
| Compound | Semax |
| CAS number | 80714-61-0 |
| Molecular formula | C37H51N9O10S |
| Molecular weight | 813.93 g/mol |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Single-letter sequence | MEHFPGP |
| Residue count | 7 |
| Structural description | ACTH(4-7) with a C-terminal Pro-Gly-Pro extension |
| Parent fragment | Adrenocorticotropic hormone residues 4 to 7, Met-Glu-His-Phe |
| Stability feature | Pro-Gly-Pro tail conferring resistance to prolyl endopeptidase |
| Melanocortin activity | Negligible. The fragment lacks the residues required for melanocortin receptor engagement |
| Reported research association | Brain-derived neurotrophic factor (BDNF) expression |
| Oxidation-prone residue | Methionine at position 1 |
| Originating institution | Institute of Molecular Genetics, Russia |
| Reconstitution required | None. Supplied as solution |
| Excipient system | Not published on the product record |
| Storage | 2-8°C, protected from light |
| Purity | Per lot-specific certificate of analysis |
| Regulatory status | Marketed in Russia and neighbouring states. No approved formulation in the United States or European Union |
Met-Glu-His-Phe-Pro-Gly-Pro divides cleanly into two functional halves, and reading it that way explains the design.
The first four residues, Met-Glu-His-Phe, correspond to residues 4 through 7 of adrenocorticotropic hormone. ACTH is a 39-residue hormone, and this short internal fragment had been investigated for behavioural activity independently of the hormone full endocrine role.
The last three, Pro-Gly-Pro, are not part of ACTH. They were appended deliberately, and the reason is enzymatic. Prolyl endopeptidase cleaves peptide bonds on the carboxyl side of proline residues, and a terminal Pro-Gly-Pro motif occupies that enzyme without being productively cleaved, protecting the sequence upstream.
The design objective is visible in the structure: take a short fragment with reported activity, attach a protective tail, and produce something that survives long enough in a biological environment to be useful.
Worth noting explicitly, since the ACTH parentage invites the assumption: the fragment lacks the residues required for melanocortin receptor engagement and does not carry the corticotropic activity of the full hormone.
Brain-derived neurotrophic factor is the mechanistic thread running through most of the Semax literature, and the association is reported rather than fully established.
BDNF is a neurotrophin supporting neuronal survival, differentiation and synaptic plasticity, acting principally through the TrkB receptor. It is among the most studied molecules in neuroscience, which makes it a natural place for a neuroactive peptide investigation to land.
Published work from the originating Russian group reports that Semax exposure associates with changes in BDNF expression and in the expression of its receptor. That is a transcriptional and protein-level association measured in rodent brain tissue and cell systems.
What is less clear is the intervening mechanism. A seven-residue peptide altering neurotrophin expression requires a route from the peptide to the transcriptional machinery, and that route has not been definitively mapped. No specific receptor for Semax has been identified.
That gap is the honest limit of the mechanistic story. The association is reported across multiple studies. The mechanism connecting them remains open.
Predominantly from one research tradition, and that concentration is worth understanding before relying on it.
Semax was developed at the Institute of Molecular Genetics in Russia, and the majority of primary work comes from that group and associated Russian institutions. Much of it is published in Russian-language journals or in translated form in outlets such as Neuroscience and Behavioral Physiology.
The work itself includes detailed pharmacological and molecular characterisation. The limitation is not quality but concentration: independent replication by laboratories outside Russia is sparse, and some primary sources are difficult to access in English.
Clinical use in Russia and neighbouring states is established, and the compound is marketed there. No approved formulation exists in the United States or European Union, and it has not been through the regulatory review those jurisdictions require.
For a researcher the practical guidance is to read primary sources rather than secondary summaries where possible, since the secondary literature on this compound repeats unqualified claims with some regularity.
For the Semax Disposable Self-injection Pen the methionine at position 1 is the principal vulnerability, and its position at the amino terminus makes it more exposed than a buried residue would be.
Methionine oxidises to the sulfoxide under atmospheric oxygen, adding 16 daltons, and the reaction accelerates with trace metal contamination and light exposure. In a lyophilized cake the reaction is slow. In solution it proceeds at a rate depending on dissolved oxygen, pH and what else is present.
The Pro-Gly-Pro tail that protects against enzymatic cleavage offers no protection against chemical oxidation, which is a separate process entirely. Enzymatic resistance and chemical stability are frequently conflated and are not the same property.
At 1 mg/ml the Semax Disposable Self-injection Pen is the least concentrated device in the catalogue, approximately 1.23 millimolar, which suits work at lower working concentrations with minimal dilution but means the total quantity in the device is small at 3mg.
Mass spectrometry showing a satellite peak 16 daltons above the parent indicates oxidation has occurred, and the proportion relative to the parent peak indicates how much.
Semax belongs to a small family of short ACTH-derived peptides, and placing it among them clarifies what the design is doing.
Adrenocorticotropic hormone is 39 residues. Its N-terminal region carries the melanocortin receptor pharmacophore, the sequence His-Phe-Arg-Trp around positions 6 to 9, which is shared with the melanocyte-stimulating hormones. Its C-terminal region carries other activity.
ACTH(4-10) was investigated for behavioural activity from the 1970s onward, and shorter fragments including ACTH(4-7) followed. Those studies established that short internal fragments carried activity separable from the hormone endocrine role, which is the premise Semax was built on.
Semax takes ACTH(4-7), Met-Glu-His-Phe, and adds Pro-Gly-Pro. Note what that sequence lacks: the Arg-Trp that completes the melanocortin pharmacophore. Removing those residues is why the fragment does not engage melanocortin receptors meaningfully, and it is a deliberate consequence of where the truncation was made.
Selank, another peptide from the same Russian programme, uses the same design logic on a different parent sequence, attaching a Pro-Gly-Pro tail to a tuftsin fragment. The tail is a platform strategy rather than a one-off.
Three things this page has stated and one it has not, gathered here because the compound is easy to over-describe.
No receptor has been identified for Semax. The BDNF association is measured at the level of expression, and the route from a seven-residue peptide to a transcriptional change remains unmapped.
The evidence base is concentrated in one research tradition, with limited independent replication outside it, and several primary sources are difficult to access in English.
No approved formulation exists in the United States or European Union, and clinical use elsewhere does not substitute for the regulatory review those jurisdictions require.
The thing not yet stated: pharmacokinetic data for Semax is thin. Half-life figures circulate without traceable primary sources, and for a seven-residue peptide the Pro-Gly-Pro tail extends enzymatic survival without making it a long-acting compound.
Inspect for clarity and particulate before each draw, against both light and dark backgrounds. A colourless peptide solution offers no colour cue, so clarity is the only visual signal.
Verify delivered volume gravimetrically at least once. At 1 mg/ml, small volume errors translate to proportionally larger errors in delivered mass than they would at higher concentration, simply because there is less compound per unit volume to begin with.
Let the device reach ambient temperature before actuating, and discard rather than measure the first actuation after any rest period.
Keep the device at 2-8°C away from light, and return it to its packaging whenever it is not in use. Light exclusion matters here for the methionine specifically rather than as a general precaution. Record lot, date of first actuation, storage conditions and volume drawn per session.
At 1 mg/ml the Semax Disposable Self-injection Pen is the least concentrated device across all three tranches, and the consequence is worth stating rather than leaving implicit.
Three millilitres at 1 mg/ml is 3mg of total peptide, which is a small quantity for a device intended to serve across multiple sessions. A study consuming more than a few hundred micrograms will exhaust it quickly.
The advantage is that minimal dilution is needed for many applications, which removes serial steps and the error they contribute.
The disadvantage is that volume errors matter proportionally more, because a given volumetric inaccuracy translates into a larger fractional error in delivered mass when there is less compound per millilitre to begin with.
Verified against publisher records or primary indexes. Read the list with the caveat above regarding concentration of primary work in one research tradition.
What is the Semax Disposable Self-injection Pen?
A preloaded 3ml research device holding Semax in solution at 1mg/ml, giving 3mg total and roughly 1.23 millimolar. Semax is a seven-residue peptide, CAS 80714-61-0, molecular weight 813.93. Laboratory research use only.
What does the sequence MEHFPGP describe?
Two functional halves. Met-Glu-His-Phe matches residues 4 through 7 of adrenocorticotropic hormone. Pro-Gly-Pro is not part of ACTH at all and was appended deliberately, because prolyl endopeptidase occupies that motif without productively cleaving it.
Does Semax have ACTH activity?
No. The fragment lacks the residues required for melanocortin receptor engagement and does not carry the corticotropic activity of the full 39-residue hormone. The ACTH parentage describes where the sequence came from, not what it does.
What is the BDNF association?
Published work from the originating group reports that Semax exposure associates with changes in brain-derived neurotrophic factor expression and in expression of its TrkB receptor, measured in rodent brain tissue and cell systems. It runs through most of the literature.
Is the BDNF mechanism established?
Not fully. A seven-residue peptide altering neurotrophin expression requires a route from peptide to transcriptional machinery, and that route has not been definitively mapped. No specific receptor for Semax has been identified, which is the honest limit of the mechanistic story.
Where does the research come from?
Predominantly the Institute of Molecular Genetics in Russia and associated institutions, published in Russian-language journals or in translation. The work is detailed, but independent replication outside Russia is sparse and some primary sources are hard to access in English.
What is the regulatory status?
Marketed in Russia and neighbouring states, where clinical use is established. No approved formulation exists in the United States or European Union, and the compound has not been through the regulatory review those jurisdictions require. This device is research material.
What is the main stability concern in solution?
The methionine at position 1, which oxidises to the sulfoxide under atmospheric oxygen, adding sixteen daltons. Sitting at the amino terminus leaves it more exposed than a buried residue would be, and trace metals and light both accelerate it.
Does the Pro-Gly-Pro tail protect against that?
No, and the two are frequently conflated. The tail confers resistance to prolyl endopeptidase, which is enzymatic cleavage. Chemical oxidation of methionine is an entirely separate process, and enzymatic resistance offers no protection against it.
Why does volume accuracy matter more at 1 mg/ml?
Because there is less compound per unit volume, so a given volume error translates to a proportionally larger error in delivered mass than the same error would at 5 or 10 mg/ml. This is the least concentrated device in the catalogue.
How does Semax relate to other ACTH fragments?
It belongs to a small family of short ACTH-derived peptides. ACTH(4-10) was investigated for behavioural activity from the 1970s, and shorter fragments including ACTH(4-7) followed, establishing that short internal fragments carried activity separable from the hormone endocrine role.
Why does Semax lack melanocortin activity?
Because the truncation removes the Arg-Trp that completes the melanocortin pharmacophore. ACTH carries His-Phe-Arg-Trp around positions 6 to 9, and Semax stops at position 7, taking Met-Glu-His-Phe only. The omission is a deliberate consequence of where the cut was made.
Is the Pro-Gly-Pro tail unique to Semax?
No, it is a platform strategy. Selank, another peptide from the same Russian programme, applies the same approach to a tuftsin fragment. Attaching a prolyl endopeptidase-occupying tail to a short active sequence is the shared design principle.
The Semax Disposable Self-injection Pen is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, and while Semax is marketed in Russia and neighbouring states, no approved formulation exists in the United States or European Union. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
The same verification the labs that use our compounds demand — documented, transparent, and enforced on every order.
Independent HPLC and mass-spec testing confirms identity and purity on every batch.
A full certificate of analysis is published and downloadable for every lot we ship.
Tracked, discreet packaging with reshipment coverage on qualifying orders.
Orders confirmed before 12 PM PT on business days ship the same day from our US-based facility.
Enter your details to access our catalog, COA library,
and research compound database.
By submitting you agree to receive email communications from Epic Peptides Lab You can unsubscribe at any time. All products for in vitro research use only.
Restock alerts, new compounds and fresh lab results.
We’ll email your code straight away – 15% off, one-time use.
Research updates only. Unsubscribe any time.
Reviews
There are no reviews yet.